

Nicole C T Van Grieken

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2390600/publications.pdf>

Version: 2024-02-01

82
papers

7,165
citations

172457

29
h-index

74163

75
g-index

82
all docs

82
docs citations

82
times ranked

9858
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial. <i>Gastric Cancer</i> , 2022, 25, 401-410.	5.3	12
2	Tumor immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. <i>Journal of Pathology</i> , 2022, 256, 282-296.	4.5	11
3	Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials. <i>Gastric Cancer</i> , 2022, 25, 640-651.	5.3	10
4	Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case-control study. <i>British Journal of Cancer</i> , 2022, 126, 865-873.	6.4	6
5	Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III trial AGITG-MAX. <i>International Journal of Cancer</i> , 2022, 151, 1166-1174.	5.1	1
6	Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. <i>Cancers</i> , 2022, 14, 2963.	3.7	0
7	Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT). <i>Clinical Cancer Research</i> , 2021, 27, 3351-3359.	7.0	143
8	Molecular profiles of response to neoadjuvant chemoradiotherapy in oesophageal cancers to develop personalized treatment strategies. <i>Molecular Oncology</i> , 2021, 15, 901-914.	4.6	7
9	Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. <i>Nature Communications</i> , 2021, 12, 1270.	12.8	111
10	Interferon- and STING-independent induction of type I interferon stimulated genes during fractionated irradiation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 161.	8.6	16
11	Circulating tumor DNA (ctDNA) analysis by low-coverage whole genome sequencing (lcWGS) of resectable esophageal adenocarcinoma (rEAC) patients. <i>Journal of Clinical Oncology</i> , 2021, 39, 4033-4033.	1.6	0
12	Risk Factors for Metachronous Isolated Peritoneal Metastasis after Preoperative Chemotherapy and Potentially Curative Gastric Cancer Resection: Results from the CRITICS Trial. <i>Cancers</i> , 2021, 13, 4626.	3.7	6
13	¹⁸ F-Fludeoxyglucose-Positron Emission Tomography/Computed Tomography and Laparoscopy for Staging of Locally Advanced Gastric Cancer. <i>JAMA Surgery</i> , 2021, 156, e215340.	4.3	31
14	Interobserver, intraobserver, and interlaboratory variability in reporting pT4a colon cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 219-230.	2.8	12
15	IBD-Associated Dysplastic Lesions Show More Chromosomal Instability Than Sporadic Adenomas. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 167-180.	1.9	29
16	Towards Personalization in the Curative Treatment of Gastric Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 614907.	2.8	10
17	DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 104-119.	6.9	51
18	Gastric cancer. <i>Lancet, The</i> , 2020, 396, 635-648.	13.7	2,084

#	ARTICLE	IF	CITATIONS
19	Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020, 10, 9778.	3.3	5
20	Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 1738.	2.4	15
21	Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. <i>Oncologist</i> , 2020, 25, e634-e643.	3.7	33
22	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. <i>Nature Communications</i> , 2020, 11, 525.	12.8	158
23	Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome. <i>Cancers</i> , 2020, 12, 330.	3.7	11
24	EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): An open-label randomized controlled phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS467-TPS467.	1.6	7
25	Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors. <i>Cancers</i> , 2019, 11, 1181.	3.7	16
26	Circulating Tumor DNA Analysis: Clinical Implications for Colorectal Cancer Patients. A Systematic Review. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz042.	2.9	22
27	Synoptic reporting increases quality of upper gastrointestinal cancer pathology reports. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 255-259.	2.8	20
28	Genome-wide cell-free DNA fragmentation in patients with cancer. <i>Nature</i> , 2019, 570, 385-389.	27.8	764
29	Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival. <i>Annals of Surgery</i> , 2019, 270, 1096-1102.	4.2	28
30	VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or Tj ETQq0 0 0 qBT /Overlock 10 Tf		
31	A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4045-4045.	1.6	20
32	A comparison of elderly versus nonelderly patients in the CRITICS gastric cancer trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 81-81.	1.6	1
33	Comparison of phosphoproteomic profiles in left- and right-sided colorectal cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 582-582.	1.6	0
34	Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 616-628.	10.7	397
35	Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial. <i>Annals of Surgery</i> , 2018, 268, 1008-1013.	4.2	27
36	Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. <i>Journal of Clinical Oncology</i> , 2018, 36, 2052-2060.	1.6	26

#	ARTICLE	IF	CITATIONS
37	Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018, 9, 4112.	12.8	55
38	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. <i>BMC Cancer</i> , 2018, 18, 877.	2.6	115
39	Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2018, 25, 2681-2692.	1.5	74
40	Combination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer. <i>PLoS ONE</i> , 2018, 13, e0201809.	2.5	20
41	Quality of life in the CRITICS study, a multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4060-4060.	1.6	2
42	Circulating tumor DNA dynamics in resectable gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4069-4069.	1.6	2
43	MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer. <i>Oncotarget</i> , 2018, 9, 29445-29452.	1.8	9
44	A machine-learning approach for the identification of highly predictive germline SNPs as biomarkers for response to bevacizumab in metastatic colorectal cancer using Elastic Net and Lasso.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15584-e15584.	1.6	1
45	Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection. <i>Journal of Proteomics</i> , 2017, 162, 99-107.	2.4	31
46	Why is colon cancer survival improving by time? A nationwide survival analysis spanning 35 years. <i>International Journal of Cancer</i> , 2017, 141, 531-539.	5.1	22
47	Irreversible Electroporation to Treat Malignant Tumor Recurrences Within the Pelvic Cavity: A Case Series. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1631-1640.	2.0	10
48	Direct detection of early-stage cancers using circulating tumor DNA. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	808
49	Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary. <i>Journal of Thoracic Disease</i> , 2017, 9, S843-S850.	1.4	17
50	Identification of a novel predictive genomic biomarker for response to combination bevacizumab in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3580-3580.	1.6	2
51	Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 42949-42961.	1.8	42
52	Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 63140-63154.	1.8	19
53	Abstract LB-246: Detection of circulating tumor DNA in early stage cancers. , 2017, , .		0
54	Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence. <i>British Journal of Cancer</i> , 2016, 115, 1565-1574.	6.4	34

#	ARTICLE	IF	CITATIONS
55	Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative. <i>Digestion</i> , 2016, 94, 129-137.	2.3	10
56	A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer. <i>BMC Cancer</i> , 2016, 16, 513.	2.6	76
57	A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4000-4000.	1.6	59
58	EORTC-1203: Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive stomach cancerâ€”INNOVATION trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS4133-TPS4133.	1.6	2
59	Mass spectrometry-based phosphoproteomics of tumor needle biopsies from patients (pts) with advanced solid tumors during treatment with protein kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11609-11609.	1.6	0
60	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. <i>Gut</i> , 2015, 64, 1721-1731.	12.1	197
61	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers. <i>Journal of Medical Genetics</i> , 2015, 52, 361-374.	3.2	479
62	Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases: The randomized phase III CAIRO5 study of the Dutch Colorectal Cancer Group.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3622-TPS3622.	1.6	2
63	Comparison of deep sequencing miRNA expression analysis in primary colorectal cancer and paired metastases.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14682-e14682.	1.6	0
64	Genomic landscape of metastatic colorectal cancer. <i>Nature Communications</i> , 2014, 5, 5457.	12.8	61
65	pT4 stage II and III colon cancers carry the worst prognosis in a nationwide survival analysis. Shepherd's local peritoneal involvement revisited. <i>International Journal of Cancer</i> , 2014, 135, 467-478.	5.1	53
66	Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. <i>Cellular Oncology (Dordrecht)</i> , 2014, 37, 353-361.	4.4	43
67	ImmunoPET imaging with 89Zr-cetuximab in patients with advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11102-11102.	1.6	2
68	Laparoscopic Sentinel Lymph Node Identification in Patients with Colon Carcinoma Using a Near-Infrared Dye: Description of a New Technique and Feasibility Study. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2013, 23, 367-371.	1.0	45
69	Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. <i>Gut</i> , 2013, 62, 1100-1111.	12.1	139
70	Association of DNA promoter hypermethylation of decoy receptor 1 (DCR1) with poor response to irinotecan in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3552-3552.	1.6	0
71	Chromosome 5q Loss in Colorectal Flat Adenomas. <i>Clinical Cancer Research</i> , 2012, 18, 4560-4569.	7.0	30
72	Iron Deficiency After Nonâ€”Small Cell Lung Cancer. <i>Gastroenterology</i> , 2012, 142, e3-e4.	1.3	23

#	ARTICLE	IF	CITATIONS
73	Comprehensive Mutation Analysis in Colorectal Flat Adenomas. PLoS ONE, 2012, 7, e41963.	2.5	20
74	Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. Journal of Pathology, 2012, 228, 31-44.	4.5	125
75	Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma. Cancer, 2012, 118, 349-357.	4.1	14
76	Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer, 2011, 11, 329.	2.6	175
77	Biopsy Strategies for Endoscopic Surveillance of Pre-malignant Gastric Lesions. Helicobacter, 2010, 15, 259-264.	3.5	65
78	Increased risk of esophageal squamous cell carcinoma in patients with gastric atrophy: Independent of the severity of atrophic changes. International Journal of Cancer, 2009, 124, 2135-2138.	5.1	26
79	Distinct chromosomal aberrations in Epstein-Barr virus-carrying gastric carcinomas tested by comparative genomic hybridization. Gastroenterology, 2001, 121, 612-618.	1.3	40
80	Quantitative assessment of gastric corpus atrophy in subjects using omeprazole: a randomized follow-up study. American Journal of Gastroenterology, 2001, 96, 2882-2886.	0.4	9
81	Rapid quantitative assessment of gastric corpus atrophy in tissue sections. Journal of Clinical Pathology, 2001, 54, 63-69.	2.0	21
82	Helicobacter pylori-related and -non-related gastric cancers do not differ with respect to chromosomal aberrations. Journal of Pathology, 2000, 192, 301-306.	4.5	39